Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass

G. Lupoli, C. Di Carlo, V. Nuzzo, G. Vitale, D. Russo, S. Palomba, C. Nappi

Research output: Contribution to journalArticle

Abstract

Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

Original languageEnglish
Pages (from-to)493-496
Number of pages4
JournalJournal of Endocrinological Investigation
Volume20
Issue number8
Publication statusPublished - Sep 1997

Keywords

  • Bone mineral density
  • Gonadotropin-releasing hormone agonists
  • Osteopenia
  • Osteoporosis
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass'. Together they form a unique fingerprint.

  • Cite this